Back to Newsroom

Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative OphthalmologyTM, announced today that data will be presented at the 11th International Congress on Systemic Lupus Erythematosus, taking place in Vienna, Austria from September 2-6.

Click here to read more